Pulmonary inflammation, abnormalities in type II cell and macrophage morphology, and pulmonary fibrosis are features of Hermansky-Pudlak Syndrome (HPS), a recessive disorder associated with intracellular trafficking defects. We have previously reported that "Pearl" (HPS2) and "Pale Ear" (HPS1) mouse models have pulmonary inflammatory dysregulation and constitutive alveolar macrophage (AM) activation (Young LR et al, J Immunol 2006). In the current study, we used these HPS models to investigate mechanisms of lung fibrosis. Unchallenged HPS1 and HPS2 mice have subtle airspace enlargement and foamy AMs, but little or no histologic evidence of lung fibrosis.
Introduction
Hermansky-Pudlak Syndrome (HPS) is a rare autosomal recessive disorder characterized by albinism, platelet dysfunction, and highly penetrant and frequently fatal pulmonary fibrosis(1, 2).
There are currently eight genetic loci known to be associated with HPS in humans (3) . Mutations in HPS genes result in defects in intracellular protein trafficking and in the biogenesis of lysosomes and lysosome-related organelles including melanosomes, platelet dense granules, and lamellar bodies in alveolar type II cells (4) . Patients with HPS exhibit alveolar inflammation well before fibrosis is apparent, with accumulation of activated alveolar macrophages (AM) and elevated levels of pro-inflammatory cytokines and chemokines in bronchoalveolar lavage (BAL) fluid (5) . Both the usual interstitial pneumonitis (UIP) pattern and cellular non-specific interstitial pneumonitis (NSIP) pattern found in idiopathic pulmonary fibrosis (IPF) have been reported in HPS, but ceroid accumulations in alveolar macrophages, large hyperplastic alveolar type II cells with swelling and foamy degeneration, and lymphocytic and histiocytic infiltration of respiratory bronchioles are distinguishing features (6, 7) . Clinically apparent pulmonary fibrosis develops in most individuals with HPS in the fourth or fifth decades of life (8) . Potential contributions of environmental factors in HPS lung disease are not known, and it remains unclear how HPS trafficking abnormalities promote fibrosis.
Mouse models of HPS share many aspects of the human disease phenotype and provide the opportunity to investigate mechanisms of human disease from the vantage point of a known genetic defect. Ten of the currently available HPS mouse models, including the HPS1 "Pale Ear" and HPS2 "Pearl" mouse models utilized in this study, are naturally occurring and are maintained as congenic mutants on the C57BL/6J inbred strain. The gene product of HPS2 in Pearl mice and humans with HPS2 is the β3A subunit of the adaptor protein-3 (AP-3) complex, a hetero-oligomer of four subunits (µ3a, σ3, δ, and β3) which functions in organelle biogenesis and protein trafficking (9) .
Mutations in individual AP-3 subunits result in instability and ubiquitin-mediated degradation of the Young et al, page 5 entire AP-3 complex, which leads to abnormalities in intracellular trafficking in a variety of cell types and organ systems. The "Pale Ear" HPS1 mouse is the model for the most common HPS subtype,
and although the precise function of the HPS1 gene product (HPS1) remains unknown, it is also clearly critical for intracellular protein trafficking.
Other human diseases provide evidence that abnormal protein trafficking in type II cells can cause interstitial lung disease (ILD) (10, 11) . Mutations in surfactant protein C (SP-C) cause SP-C protein misfolding and activation of endoplasmic reticulum (ER) stress pathways (12) , and the adaptation to the chronic ER stress is associated with an increased susceptibility to RSV-induced death of type II cells (13) . Mutations in the ATP-binding cassette family member of proteins, ABCA-3 gene, affect lipid transport into lamellar bodies, and also cause ILD through type II cell-dependent mechanisms (14, 15) . Apoptosis of alveolar type II cells is also a prominent feature of many types of ILD, and correlates with disease progression in IPF and extent of fibrosis in animal models (16, 17) .
Pearl and Pale Ear HPS mice have been shown to have structural abnormalities in the alveolar compartment that are similar to those observed in humans with HPS, including foamy AMs and enlarged type II cells containing irregular dense inclusions (6, 18) , and expansion of interstitial septa by excess collagen fibrils at the ultrastructural level (18) . Others have shown that double-mutant HPS1/HPS2 (ep/pe) mice have impaired lamellar body secretion from type II cells (19) , and that lung hydroxyproline content is significantly increased compared with controls (20) . Furthermore, silicachallenged Pale Ear mice develop a persistent accumulation of activated macrophages and increased collagen fibers in alveolar tissues (21) . However, unchallenged Pearl and Pale Ear mice do not spontaneously develop histologically significant pulmonary fibrosis by one year of age, but instead exhibit progressive airspace enlargement (20) . Therefore, whether the phenotype of HPS mouse models includes susceptibility to pulmonary fibrosis has remained controversial.
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We have previously demonstrated that Pearl and Pale Ear mice have basal inflammatory dysregulation and constitutive AM activation that parallels abnormalities reported in HPS patients (5, 22) . We wondered whether HPS mice would develop enhanced fibrosis in response to inhalation challenge with bleomycin. Bleomycin is a chemotherapeutic agent known to induce the release of cytokines, augment fibroblast proliferation and activity, and to cause human and animal lung parenchymal injury and subsequent lung fibrosis. Therefore, we investigated the responses of HPS mice to intratracheal (IT) bleomycin challenge.
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Materials and Methods
Mice
Breeding pairs of pearl (HPS2 mutation) and pale ear (HPS1 mutation) mice that had been maintained on the C57BL/6J background were gifts from Dr. R. Swank (Roswell Park Cancer Institute, Buffalo, NY). C57BL/6J mice (Jackson, Bar Harbor, Maine) were used as the wild-type (WT) control (referred to as WT thereafter) for comparisons with HPS mice. Mice were housed in a barrier facility and studied using procedures approved by the University of Cincinnati Institutional Animal Care and Use Committee. Sentinel mice that were tested periodically were free of known viral and bacterial pathogens. Male mice, age 8-14 weeks, were utilized for all studies.
Bleomycin challenge
Mice were anesthetized to moderate depth with isofluorane (Forane; Ohmeda Caribe). After topical sterilization with ethanol, the trachea was minimally exposed via a ventral midline neck incision and cannulated with a sterile catheter. Bleomycin sulfate (0.025 -0.05 units/mouse) (Sigma, St. Louis. MO) or saline control was instilled intratracheally (IT), the incision was closed with surgical adhesive, and the mice were observed through recovery.
Lung histology and immunohistochemistry (IHC)
Animals were sacrificed by pentobarbital injection, and 0.9 mL of 10% buffered formalin was instilled into the lungs via a tracheal cannula at 25cm H 2 0. Lung tissues were paraffin embedded and cut in 5-μm sections by conventional methods. Slides were stained with hematoxylin and eosin (H&E) or trichrome blue. Endogenous peroxidase activity was blocked with immersion of deparaffinized sections in 3% H 2 O 2 for 10 minutes. For antigen retrieval, the sections were placed in 0.1M citrate buffer, pH 6.0, and treated with microwave for 10 minutes. Type II cells were identified using a rabbit polyclonal antibody against human pro-SPC (kind gift of J. Whitsett, MD) (dilution Samples were then centrifuged, unbound dye solution was removed, and the remaining collagenbound dye pellet was solubilized. Absorbance was measured at 540nm and compared with a calibration curve generated using the collagen standard provided by the manufacturer.
Evaluation of airway and tissue cellular recruitment
Mice were sacrificed by lethal pentobarbital injection followed by transection of the abdominal aorta. BAL was performed as described, after tracheostomy and intubation with a sterile 20-gauge adapter, by gentle instillation and aspiration of three 1-ml aliquots of 0.9% saline with 5 mM Tris.
After separation of the BAL cells by low-speed centrifugation (450 x g, 10 min, 4°C), the cell-free BAL fluid was stored at -80°C until use. Cells were resuspended in PBS and counted using a
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Coulter counter or hemacytometer. A cell aliquot was spun onto glass slides using a cytocentrifuge 
ELISA measurements of cytokines and chemokines
Cytokine protein concentrations in cell-free BAL, lung homogenate, and AM cell culture media supernatant were quantified by ELISA (murine Quantikine kits; R&D Systems, Minneapolis, MN), using the chromogenic substrate tetramethylbenzidine and analysis with a microtiter plate spectrophotometer at a wavelength of 450 nm.
Evaluation of apoptosis
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) was performed on deparaffinized lung tissue sections using the In Situ Cell Death detection kit (Roche Diagnostics, 
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Statistical Analysis
Numeric data are presented as mean ± SEM. Parametric data were evaluated using the Student t test, or by one-way ANOVA for comparison of more than two groups (Prism 4, Graph Pad Software, Inc., San Diego,CA). The log rank test was used for survival analysis. P-values <0.05 were considered significant.
Results
Pearl mice have increased mortality when exposed to intratracheal bleomycin.
Pearl mice were challenged with IT bleomycin (or saline control) at doses (0.025 and 0.05 units/mouse in volume of 50µL) that are considered sub-lethal for this mouse strain (24, 25) . As shown in Figure 1 , bleomycin challenge led to significantly greater mortality in Pearl than WT mice.
Bleomycin at a dose of 0.05 units/mouse resulted in 100% mortality in Pearl mice after seven days 
Pearl mice have reduced lung compliance after bleomycin challenge.
In order to determine if the observed histologic changes were associated with significant physiologic impairment, a forced oscillation technique was used to assess pulmonary compliance in Pearl mice.
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While no significant physiologic changes were detected in bleomycin-treated WT mice at the 7 day point, quasi-static and static compliance were significantly decreased in bleomycin-challenged Pearl mice (0.046 ± 0.003 mL/cm H 2 0 for Pearl vs. 0.066 ± 0.006 mL/cm H 2 0 for WT, p< 0.05) after one week (Figure 4 ).
Airway and pulmonary inflammatory cell recruitment in Pearl mice is similar to WT mice after intratracheal bleomycin challenge.
Intratracheal bleomycin challenge is associated with a robust early cellular inflammatory response (25, 26) . We have previously reported that total BAL cell numbers and differentials are not significantly different at baseline in Pearl, Pale Ear, and WT mice (22) . After IT bleomycin challenge, total BAL cell numbers were increased, and cell differentials were similar in Pearl and WT mice at one and three days ( Figure 5A and B) . Both WT and Pearl mice had a neutrophil-rich cellular influx which peaked at approximately day three. Lymphocytes were also recruited to the airspace. A modest influx of eosinophils also occurred in both WT and Pearl mice (not shown).
Using FACS analysis, total lung leukocyte cell numbers and proportions of neutrophils, macrophages, and lymphocytes were found to be similar in Pearl and WT mice three days after IT bleomycin (not shown).
HPS mice have elevated levels of profibrotic, but not pro-inflammatory, mediators after bleomycin challenge.
Bleomycin-induced fibrosis in animal models has been shown to be associated with production of profibrotic mediators including TGFβ1 and IL12 (27, 28) . While the level of TGFβ1 was similar in the pulmonary tissues of unchallenged Pearl, Pale Ear, and WT mice, elevated levels of activated 
Apoptosis is increased in the lungs of HPS mice after bleomycin challenge.
To investigate mechanisms of the fibrotic susceptibility in HPS mice, TUNEL assay was used to screen for apoptosis in pulmonary cells after low dose IT bleomycin challenge. 
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Discussion
These experiments provide a comprehensive assessment of the response of Pearl mice to bleomycin challenge and demonstrate that Pearl and Pale Ear HPS mouse models have a pulmonary phenotype that includes fibrotic susceptibility. Although C57BL/6J is a mouse strain known for susceptibility to bleomycin-induced fibrosis (25, 29) , the WT animals were only modestly affected at the seven day timepoint by the bleomycin doses which induced diffuse fibrosis and mortality in strain-matched HPS mice. Bleomycin-challenged HPS mice also exhibited increased weight loss, histologic evidence of fibrosis, and biochemical evidence of collagen deposition as compared to strain-matched WT mice. These findings in Pearl mice were associated with reduced pulmonary compliance consistent with a restrictive physiologic defect. These data support the use of HPS mice as models of pulmonary fibrosis.
HPS ranks among the most penetrant genetic disorders of pulmonary fibrosis in adults, as virtually all HPS patients who survive to adulthood develop fibrotic lung disease (1, 30) . HPS1 is the most common human genotype, and accounts for the majority of ILD cases reported in HPS. Although the eight reported HPS2 patients are younger in age than HPS1 and HPS4 patients with pulmonary fibrosis, mild pulmonary fibrosis was described in two HPS2 cases (31, 32) . In this study, key findings of bleomycin-induced histologic fibrosis and alveolar type II cell apoptosis in the HPS2 mice were also confirmed in Pale Ear HPS1 mice, the more common genetic background associated with fibrosis.
The role of cellular inflammation in ILD pathogenesis remains unclear. While idiopathic pulmonary fibrosis (IPF) is increasingly recognized as a pauci-immune disorder with fibroblastic proliferation but relatively minimal leukocyte infiltration, robust cellular interstitial inflammation precedes fibrosis in multiple other forms of ILD such as hypersensitivity pneumonitis, sarcoidosis, desquamative interstitial pneumonitis, respiratory bronchiolitis, and ILD associated with mutations in SP-C and
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connective tissue disease (33) (34) (35) . Alveolar inflammation also precedes pulmonary fibrosis in patients with HPS(5), but the direct role of inflammation in the pathogenesis of HPS lung disease has not been determined. We have previously reported that Pearl and Pale Ear mice exhibit pulmonary inflammatory dysregulation, with constitutive alveolar macrophage activation and exaggerated cytokine responses to endotoxin challenge (22) . In the bleomycin model of pulmonary fibrosis, inflammation induces the release of cytokines that promote fibroblast proliferation and production of extracellular matrix (26, 36) . In this context, we postulated that Pearl mice would have an aberrant early and exaggerated inflammatory response to bleomycin challenge. However, similar elevations in selected pro-inflammatory cytokines and chemokines, and in early airway and parenchymal cellular inflammatory recruitment, occurred in Pearl and WT mice following bleomycin challenge. Further studies are needed to determine whether pulmonary inflammation and fibrosis are causally linked in HPS.
Profibrotic cytokines such as TGFβ cause fibroblast transformation and proliferation, leading to deposition of extracellular matrix (37, 38) , and multiple studies have demonstrated that TGFβ is a key factor in fibrosis in the lung and in other tissues. In animal models, adenoviral-driven overexpression of TGFβ1 results in pulmonary fibrosis, and blocking the action of TGFβ attenuates fibrosis (28, 37, 39) . Our studies revealed greater elevations in levels of TGFβ in the lungs of bleomycin-challenged HPS than WT mice. Further, isolated murine HPS AMs produced excess quantities of TGFβ in comparison to WT AMs after bleomycin challenge. In addition, IL-12/23p40, but not IL-12p70, was constitutively produced by HPS AMs and found in elevated levels in the lungs of HPS versus WT mice, both at baseline and after bleomycin challenge. Previous studies have demonstrated that the profibrotic IL-12p40 subunit, but not the IL-12p70 heterodimer, is overproduced during experimental induction of fibrosis, and that alveolar macrophages are the predominant source (40) . Further, IL-12p40 -/-mice are resistant to silica-induced fibrosis (41) , and a monoclonal antibody to IL12 was protective in the bleomycin model (27) . Together, our findings of increased IL-12p40 and TGFβ production from HPS AMs suggest a possible link between macrophage dysfunction and fibrogenesis in HPS.
In addition to cytokine/chemokine imbalance, many studies support the concept that alveolar epithelial cell apoptosis is a dominant feature of human fibrotic lung disease and pulmonary fibrosis in the bleomycin model (42) . In lung biopsies from patients with IPF, alveolar epithelial cell apoptosis has been found in regions adjacent to myofibroblasic proliferation and collagen deposition (16, 43) . Among the fibrogenic factors we assessed, the earliest distinguishing finding between HPS and WT mice following bleomycin challenge was apoptosis of type II cells. TUNEL staining revealed apoptosis of alveolar type II cells as early as five hours after bleomycin challenge in HPS mice, and the subsequent increase in caspase-3 activation indicates that the initial DNA fragmentation and cellular injury was followed by apoptotic cell death. Our data suggest that type II cell susceptibility to apoptosis may play a role in the fibrotic response, although the absolute extent of type II cell apoptosis required to induce fibrosis is not known. Bleomycin challenge induced increased levels of TGFβ1 in HPS mice, and TGFβ1 has been shown to enhance Fas-mediated epithelial cell apoptosis and pulmonary fibrosis (44) . However, our data would suggest that TGFβ is not the sole contributor to Pearl type II cell apoptosis and fibrosis, as apoptosis, which occurred as early as 5 hours after bleomycin challenge, preceded a detectable increase in TGFβ levels in vivo. 
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Fas ligand antibody prevents bleomycin-induced epithelial apoptosis and pulmonary fibrosis (46) , as do caspase inhibitors (47) . Furthermore, experimental induction of apoptosis in mice via inhalation of anti-Fas antibody has been shown to result in pulmonary fibrosis (48) .
We have previously reported that Pearl mice have increased basal pulmonary levels of sFas (22) .
Based on knowledge that FasL is a member of the TNF family which is expressed predominantly in the lytic granule of activated T lymphocytes and natural killer cells (49) , and that AP-3 has previously been shown to be critical for the movement of T-cell lytic granules to the immunological synapse(50), we hypothesized that AP-3 deficiency in Pearl mice would lead to abnormalities in the Fas/FasL system that would promote apoptosis via an extrinsic pathway. However, we found no baseline differences in expression of Fas receptor or FasL by ELISA or immunohistochemistry.
While levels of FasL were elevated in Pearl mice as compared to WT mice, the difference did not occur until seven days after bleomycin challenge, the timepoint at which fibrosis was already evident.
An intrinsic apoptotic mechanism is perhaps more likely in HPS-affected cells. The finding that alveolar apoptosis is increased in both HPS2 and HPS1 mice suggests a common, mistraffickingmediated mechanism of apoptotic susceptibility that is not genotype-specific. SP-C misfolding mutations are associated with marked phenotypic variability with respect to penetrance, age of onset, and disease severity (10, 11) . Evidence of ER stress(13) and susceptibility to bleomycin induced apoptosis and fibrosis from SP-C models (17) suggests that environmental insults, which overwhelm the homeostatic activities of marginally compensated type II cells, may provide a "second hit" which leads to fibrosis. Future studies are planned to investigate mechanisms of HPS type II cell apoptotic susceptibility.
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Although many animal models of pulmonary fibrosis exist, the bleomycin model is one of the most widely studied. Bleomycin is associated with a myriad of injurious effects, and numerous mechanisms have been postulated to influence the outcome of bleomycin-challenge. This study identifies HPS mice as a promising and experimentally tractable model to examine the molecular basis of pulmonary fibrosis using genetic and cellular replacement techniques.
In summary, we conclude that HPS mice exhibit susceptibility to bleomycin-induced alveolar type II cell apoptosis, pulmonary fibrosis, and mortality. Cellular and molecular insights into the pathogenesis of HPS lung disease may enhance the understanding and therapeutic approach to more common fibrotic lung disorders. At indicated timepoints after IT bleomycin (0.025 units), lungs were inflation-fixed in formalin as
